TL;DR
This study explores how low pressure and hypoxia (LPH), mimicking high-altitude environments, can influence cancer prognosis. Researchers developed a pan-cancer risk model using ADME genes that are sensitive to LPH, finding that this environment may improve survival by downregulating these genes and increasing T-cell infiltration. The work also identifies potential drug targets for LPH-assisted cancer treatment.
What Problem Does This Paper Address?
Current cancer treatments, while advancing, still face limitations and can cause significant side effects. Interestingly, observations suggest that individuals living at high altitudes, exposed to low pressure and hypoxia (LPH), tend to have lower cancer incidence and mortality. This hints at a potential therapeutic benefit of LPH environments. However, the underlying mechanisms and how to harness this effect for cancer treatment remain largely unexplored, especially at a population data level. This paper aims to bridge this gap by investigating the role of LPH-responsive ADME (Absorption, Distribution, Metabolism, Excretion) genes in pan-cancer prognosis and exploring potential drug interventions.
Methods
The researchers employed a multi-pronged approach:
- Pan-Cancer Prognostic Model Construction: They used stepwise multivariate Cox regression to build a model predicting patient survival based on gene expression data.
- Gene Selection: A key step involved identifying ADME genes that were both responsive to LPH (using data from mountaineers) and significantly associated with overall survival (OS) in cancer patients. This involved integrating data from iron metabolism and hypoxia gene sets, followed by network association analysis (Spearman and WGCNA) and univariate Cox regression.
- LPH Impact Analysis: The AltitudeOmics dataset was crucial for understanding how LPH affects the expression of selected ADME genes over different time points and exposure durations.
- Immune Infiltration Analysis: CIBERSORT was used to assess differences in immune cell composition between high-risk and low-risk groups identified by the prognostic model, exploring the link between LPH, ADME genes, and the tumor microenvironment.
- Drug Discovery: They utilized the LINCS L1000 platform for small molecule drug prediction and performed drug docking (AutoDockTools) to identify potential therapeutic agents that could interact with the identified ADME genes. Protein-protein interaction networks (STITCH) were also used.
Datasets
- The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Unique Datasets (TARGET): These large-scale cancer genomics datasets provided gene expression and survival data for 8,628 cancer samples across 33 types of cancer, forming the basis for the pan-cancer prognostic model.
- Gene Expression Omnibus (GEO) Databases: Three GEO datasets were used for external validation of the prognostic model's predictive efficiency.
- AltitudeOmics Dataset: This dataset, specifically featuring gene expression data from individuals exposed to varying altitudes (including extreme hypoxia), was instrumental in identifying ADME genes that respond to LPH.
Key Insights and Ideas
- LPH as a Potential Cancer Adjuvant: The study provides compelling evidence that LPH environments can positively impact cancer prognosis, suggesting a novel avenue for cancer treatment beyond traditional therapies.
- ADME Genes as Key Mediators: The research highlights the critical role of specific ADME genes in mediating the effects of LPH on cancer survival, identifying a set of 8 genes that form the basis of their prognostic model.
- Downregulation of ADME Genes = Better Prognosis: A key finding is that lower expression of these ADME genes, often induced by LPH, is associated with better patient survival across many cancer types. This suggests that LPH might exert its beneficial effects by suppressing the activity of these genes.
- Immune Microenvironment Modulation: The LPH environment, through its influence on ADME genes, appears to alter the tumor immune microenvironment, leading to increased T-cell infiltration in low-risk groups, which is generally associated with a better anti-tumor response.
- Targeted Drug Discovery: The study successfully identified specific small molecule drugs that can interact with the identified ADME genes, offering potential therapeutic strategies for LPH-assisted cancer interventions.
Key Results
- An 8-gene pan-cancer prognostic model was developed using ADME genes, achieving an AUC of 0.71.
- Lower risk scores from this model were associated with better prognosis in 25 out of 33 cancer types (p < 0.05).
- The LPH environment was observed to reduce the overall expression of these 8 ADME genes, correlating with decreased tumor death risk.
- Significant differences in immune cell infiltration were found between high-risk and low-risk groups, with T-cell populations being notably higher in the low-risk group.
- Seven ADME genes showed significant changes in expression during LPH exposure, with distinct patterns observed for long-term vs. short-term exposure.
- Drug docking analysis identified 3 potential drugs (Vorinostat, Estriol, and Nicardipine) that show promising interactions with the model ADME genes.
Limitations and Future Work
- Limited Sample Size for Validation: While the study used multiple datasets for validation, the authors acknowledge that the overall sample size, particularly for external validation cohorts, is limited.
- Insufficient Evidence on LPH Regulation: The paper notes that there is currently insufficient evidence on the precise regulation of ADME genes within hypoxic environments.
- Complexity of In Vivo Environment: The drug docking and prediction results are based on computational models. The authors emphasize that the complex in vivo environment and protein interactions mean that specific drug effects need to be verified through experimental validation.
Future Work: The authors propose expanding population validation and conducting experimental studies to confirm their findings. They also aim to further explore the adjuvant effect of LPH on cancer prognosis in greater depth, aiming to reveal its intervention effects on tumor survival.
Summary updated